Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

Watson Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited; in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Net revenues $622,636 $603,005 $1,249,585 $1,274,610

Cost of sales (excludes

amortization, presented below) 359,898 360,438 740,000 785,158

Gross profit 262,738 242,567 509,585 489,452

Operating expenses:

Research and development 39,216 35,503 77,231 73,311

Selling, general and

administrative 104,295 97,158 210,928 200,376

Amortization 20,190 44,159 40,369 88,092

Total operating expenses 163,701 176,820 328,528 361,779

Operating income 99,037 65,747 181,057 127,673

Non-operating (expense)

income, net:

Loss on early extinguishment

of debt - (1,681) (1,095) (4,410)

Interest income 1,685 1,803 3,994 4,732

Interest expense (6,931) (11,475) (13,727) (25,351)

Other income 2,080 3,034 7,433 6,437

Total non-operating expense,

net (3,166) (8,319) (3,395) (18,592)

Income before income taxes 95,871 57,428 177,662 109,081

Provision for income taxes 35,568 21,019 66,730 41,060

Net income $60,303 $36,409 $110,932 $68,021

Diluted earnings per share $0.53 $0.33 $0.98 $0.62

Diluted weighted a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 CORD:USE Cord Blood ... announce that it has entered into an Equity and ... which has licensed a series of patented technologies for the ... possible clinical applications.  Tianhe is performing Phase I/II clinical ... Spain using Tianhe,s Stem Cell Educator ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
(Date:9/30/2014)... DEL MAR, Calif. , Sept. 30, 2014 /PRNewswire/ ... devices for women,s health announces its receipt of a ... The FemmyCycle menstrual cup has also received FDA clearance ... Health Canada, and the CE in Europe. This patent is ... design. In conjunction with this issuance, the company is releasing ...
Breaking Biology Technology:CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2
... The Board of Directors of Schering-Plough Corporation (NYSE: SGP ... share. Payment will be made on Aug. 31, 2009, to ... 2009. As of March 31, 2009, there were 1,628,335,093 common ... also declared a quarterly dividend of $3.75 per share on the ...
... BASEL, Switzerland, June 23 Syngenta announced today the successful ... year maturity. The proceeds of the bond will be used ... said: "We have taken advantage of favorable current borrowing conditions ... bond issue is part of our normal funding requirements and ...
... SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials ... products, announced today that the company was recently nominated ... in pediatrics. The company is among three ... device analysts in recognition of the development of REPEL-CV(TM) ...
Cached Biology Technology:Syngenta Issues EUR 500 Million Eurobond 2SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... microscope integrates two Finnish innovations and brings new dimensions ... for Molecular Medicine Finland (FIMM) have in collaboration with ... finger gesture controlled microscope. The method is a combination ... multitouch display. The result is an entirely new ...
... Congress on Osteoporosis & Osteoarthritis in Valencia, Spain, Professor ... Pierre D. Delmas Prize. The prestigious award, ... Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International ... an individual who has made outstanding and major scientific ...
... - A lot of chatter goes on inside each one ... ears. Researchers at McMaster University discovered that the "cross-talk" ... important role in the development of psychiatric illness, intestinal diseases ... "The wave of the future is full of opportunity as ...
Cached Biology News:Big size multitouch display turned into a microscope 2ESCEO-IOF Servier Pierre D. Delmas Prize awarded to John. A. Kanis 2'Knowing it in your gut' is real 2
...
TNM-FH Insect Medium 1 liter...
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Biology Products: